StarTek (SRT - Get Report) fell after the Denver-based staffing-services company said fourth-quarter earnings will probably range between $1 million and $1.3 million, or 7 cents to 9 cents a share -- less than a third of year-ago income, which had totaled $4.4 million, or 30 cents a share. Revenue is expected at $59 million, up slightly from a year ago but falling about $5.8 million short of the Street projection. StarTek says the disappointing profits stem from lower gross margins that, at about 14%, represent a 7.6-point decline from last year. Shares were receding $2.49, or 19.5%, to $10.25.Coley Pharmaceutical (COLY) slumped on news that the company will halt developing its hepatitis C drug candidate, Actilon, after a midphase study yielded unpromising results. The Wellesley, Mass., company will now focus on developing drugs that stimulate certain toll-like receptors (naturally occurring proteins that play a part in the immune system) for a product line called TLR Therapeutics. Shares were losing $1.14, or 11.5%, to $8.75.
Tuesday's Early Winners & Losers
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.